What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist

Sassine Ghanem,1 Sandy El Bitar,1 Sami Hossri,1 Chanudi Weerasinghe,2 Jean Paul Atallah2 1Department of Internal Medicine, 2Department of Hematology and Oncology, Staten Island University Hospital – Northwell Health, New York, NY, USA Abstract: Lung cancer remains the leading cause of death in cance...

Full description

Bibliographic Details
Published in:Cancer Management and Research
Main Authors: Ghanem,Sassine, El Bitar,Sandy, Hossri,Sami, Weerasinghe,Chanudi, Atallah,Jean Paul
Format: Article in Journal/Newspaper
Language:English
Published: Dove Press 2017
Subjects:
Online Access:https://www.dovepress.com/what-we-know-about-surgical-therapy-in-early-stage-non-small-cell-lung-peer-reviewed-fulltext-article-CMAR
id ftdovepress:oai:dovepress.com/33612
record_format openpolar
spelling ftdovepress:oai:dovepress.com/33612 2023-05-15T18:12:59+02:00 What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist Ghanem,Sassine El Bitar,Sandy Hossri,Sami Weerasinghe,Chanudi Atallah,Jean Paul 2017-07-06 text/html https://www.dovepress.com/what-we-know-about-surgical-therapy-in-early-stage-non-small-cell-lung-peer-reviewed-fulltext-article-CMAR en eng Dove Press info:eu-repo/semantics/altIdentifier/doi/10.2147/CMAR.S139253 https://www.dovepress.com/what-we-know-about-surgical-therapy-in-early-stage-non-small-cell-lung-peer-reviewed-fulltext-article-CMAR info:eu-repo/semantics/openAccess Cancer Management and Research Review info:eu-repo/semantics/article 2017 ftdovepress https://doi.org/10.2147/CMAR.S139253 2022-12-27T22:13:44Z Sassine Ghanem,1 Sandy El Bitar,1 Sami Hossri,1 Chanudi Weerasinghe,2 Jean Paul Atallah2 1Department of Internal Medicine, 2Department of Hematology and Oncology, Staten Island University Hospital – Northwell Health, New York, NY, USA Abstract: Lung cancer remains the leading cause of death in cancer patients. The gold standard for the treatment of early-stage non-small-cell lung cancer is lobectomy with mediastinal lymph-node dissection or systematic lymph-node sampling. The evidence behind this recommendation is based on the sole randomized controlled trial conducted to date, done by the Lung Cancer Study Group and published in 1995, which found a superiority for lobectomy over sublobar resection with regard to local recurrence rate and improved survival. The population studied at that time were medically fit patients at low risk for surgery with a stage IA non-small-cell lung carcinoma, ie, a solitary tumor less than 3 cm in size. In practice, however, thoracic surgeons have continued to push the limit of a more conservative surgical resection in this patient population. Since then, several retrospective studies have attempted to identify the ideal population to benefit from sublobar resection without it affecting survival or local recurrence. Several variables have been studied, including tumor size, patient age, surgical approach, histological and radiological properties, and optimal surgical resection margin, as well as promising prognostic biomarkers. In this review, we summarize the data available in the literature regarding the surgical approach to patients with stage IA non-small-cell lung cancer studying all the aforementioned variables. Keywords: segmentectomy, wedge resection, lung cancer, lobectomy, non-small-cell lung cancer, sublobar resection Article in Journal/Newspaper sami Dove Medical Press Cancer Management and Research Volume 9 267 278
institution Open Polar
collection Dove Medical Press
op_collection_id ftdovepress
language English
topic Cancer Management and Research
spellingShingle Cancer Management and Research
Ghanem,Sassine
El Bitar,Sandy
Hossri,Sami
Weerasinghe,Chanudi
Atallah,Jean Paul
What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist
topic_facet Cancer Management and Research
description Sassine Ghanem,1 Sandy El Bitar,1 Sami Hossri,1 Chanudi Weerasinghe,2 Jean Paul Atallah2 1Department of Internal Medicine, 2Department of Hematology and Oncology, Staten Island University Hospital – Northwell Health, New York, NY, USA Abstract: Lung cancer remains the leading cause of death in cancer patients. The gold standard for the treatment of early-stage non-small-cell lung cancer is lobectomy with mediastinal lymph-node dissection or systematic lymph-node sampling. The evidence behind this recommendation is based on the sole randomized controlled trial conducted to date, done by the Lung Cancer Study Group and published in 1995, which found a superiority for lobectomy over sublobar resection with regard to local recurrence rate and improved survival. The population studied at that time were medically fit patients at low risk for surgery with a stage IA non-small-cell lung carcinoma, ie, a solitary tumor less than 3 cm in size. In practice, however, thoracic surgeons have continued to push the limit of a more conservative surgical resection in this patient population. Since then, several retrospective studies have attempted to identify the ideal population to benefit from sublobar resection without it affecting survival or local recurrence. Several variables have been studied, including tumor size, patient age, surgical approach, histological and radiological properties, and optimal surgical resection margin, as well as promising prognostic biomarkers. In this review, we summarize the data available in the literature regarding the surgical approach to patients with stage IA non-small-cell lung cancer studying all the aforementioned variables. Keywords: segmentectomy, wedge resection, lung cancer, lobectomy, non-small-cell lung cancer, sublobar resection
format Article in Journal/Newspaper
author Ghanem,Sassine
El Bitar,Sandy
Hossri,Sami
Weerasinghe,Chanudi
Atallah,Jean Paul
author_facet Ghanem,Sassine
El Bitar,Sandy
Hossri,Sami
Weerasinghe,Chanudi
Atallah,Jean Paul
author_sort Ghanem,Sassine
title What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist
title_short What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist
title_full What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist
title_fullStr What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist
title_full_unstemmed What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist
title_sort what we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist
publisher Dove Press
publishDate 2017
url https://www.dovepress.com/what-we-know-about-surgical-therapy-in-early-stage-non-small-cell-lung-peer-reviewed-fulltext-article-CMAR
genre sami
genre_facet sami
op_relation info:eu-repo/semantics/altIdentifier/doi/10.2147/CMAR.S139253
https://www.dovepress.com/what-we-know-about-surgical-therapy-in-early-stage-non-small-cell-lung-peer-reviewed-fulltext-article-CMAR
op_rights info:eu-repo/semantics/openAccess
op_doi https://doi.org/10.2147/CMAR.S139253
container_title Cancer Management and Research
container_volume Volume 9
container_start_page 267
op_container_end_page 278
_version_ 1766185472409731072